DrugPatentWatch Database Preview
SIGNIFOR Drug Profile
When do Signifor patents expire, and what generic alternatives are available?
Signifor is a drug marketed by Novartis and Novartis Pharms Corp and is included in two NDAs. There are five patents protecting this drug.
This drug has eighty-six patent family members in thirty-nine countries.
The generic ingredient in SIGNIFOR is pasireotide pamoate. One supplier is listed for this compound. Additional details are available on the pasireotide pamoate profile page.
Summary for SIGNIFOR
International Patents: | 86 |
US Patents: | 2 |
Applicants: | 2 |
NDAs: | 2 |
Suppliers / Packagers: | 1 |
Bulk Api Vendors: | 12 |
Clinical Trials: | 7 |
Patent Applications: | 33 |
Drug Prices: | Drug price information for SIGNIFOR |
DailyMed Link: | SIGNIFOR at DailyMed |

Generic Entry Opportunity Date for SIGNIFOR
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for SIGNIFOR
Drug Class | Somatostatin Analog |
Mechanism of Action | Somatostatin Receptor Agonists |
Synonyms for SIGNIFOR
[(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[[4-(phenylmethoxy)phenyl]methyl]-3-(phenylmethyl)-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl) |
396091-73-9 |
820232-50-6 |
98H1T17066 |
AKOS030526804 |
CHEBI:72312 |
CHEBI:72313 |
CHEMBL3349607 |
CS-2328 |
Cyclo((2R)-2-phenylglycyl-d-tryptophyl-l-lysyl-o-(phenylmethyl)-l-tyrosyl-l-phenylalanyl-(4R)-4-((((2-aminoethyl)amino)carbonyl)oxy)-l-prolyl), l-aspartate (1:2) |
cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-) |
Cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L-phenylalanyl-) |
cyclo[(2S)-2-phenylglycyl-D-tryptophyl-6-azaniumyl-L-norleucyl-O-benzyl-L-tyrosyl-L-phenylalanyl-(4R)-4-{[(2-ammonioethyl)carbamoyl]oxy}-L-prolyl] bis[(2S)-2-azaniumylsuccinate] |
cyclo[(2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-benzyl-L-tyrosyl-L-phenylalanyl-(4R)-4-{[(2-aminoethyl)carbamoyl]oxy}-L-prolyl] |
cyclo[(2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-benzyl-L-tyrosyl-L-phenylalanyl-(4R)-4-{[(2-aminoethyl)carbamoyl]oxy}-L-prolyl] bis-(L-aspartate) |
D0TV0C |
DB06663 |
GTPL2018 |
HY-16381 |
I4P76SY3N4 |
pasireotida |
Pasireotide |
Pasireotide [USAN:INN] |
pasireotide aspartate |
Pasireotide diaspartate |
Pasireotide diaspartate [EMA EPAR] |
pasireotidum |
SCHEMBL12462108 |
Signifor (TN) |
Signifor LAR |
SOM 230 |
SOM 230|||SOM 320 |
SOM 320 |
SOM-230 |
SOM230 |
UNII-98H1T17066 |
UNII-I4P76SY3N4 |
US Patents and Regulatory Information for SIGNIFOR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis Pharms Corp | SIGNIFOR LAR KIT | pasireotide pamoate | FOR SUSPENSION;INTRAMUSCULAR | 203255-003 | Dec 15, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
Novartis Pharms Corp | SIGNIFOR LAR KIT | pasireotide pamoate | FOR SUSPENSION;INTRAMUSCULAR | 203255-003 | Dec 15, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
Novartis | SIGNIFOR | pasireotide diaspartate | SOLUTION;SUBCUTANEOUS | 200677-001 | Dec 14, 2012 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
Novartis Pharms Corp | SIGNIFOR LAR KIT | pasireotide pamoate | FOR SUSPENSION;INTRAMUSCULAR | 203255-002 | Dec 15, 2014 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
Novartis Pharms Corp | SIGNIFOR LAR KIT | pasireotide pamoate | FOR SUSPENSION;INTRAMUSCULAR | 203255-003 | Dec 15, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
Novartis | SIGNIFOR | pasireotide diaspartate | SOLUTION;SUBCUTANEOUS | 200677-003 | Dec 14, 2012 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
Novartis | SIGNIFOR | pasireotide diaspartate | SOLUTION;SUBCUTANEOUS | 200677-002 | Dec 14, 2012 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for SIGNIFOR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | SIGNIFOR | pasireotide diaspartate | SOLUTION;SUBCUTANEOUS | 200677-002 | Dec 14, 2012 | ➤ Sign Up | ➤ Sign Up |
Novartis | SIGNIFOR | pasireotide diaspartate | SOLUTION;SUBCUTANEOUS | 200677-001 | Dec 14, 2012 | ➤ Sign Up | ➤ Sign Up |
Novartis | SIGNIFOR | pasireotide diaspartate | SOLUTION;SUBCUTANEOUS | 200677-003 | Dec 14, 2012 | ➤ Sign Up | ➤ Sign Up |
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
International Patents for SIGNIFOR
Country | Document Number | Estimated Expiration |
---|---|---|
South Korea | 101124136 | ➤ Sign Up |
Mexico | PA03000991 | ➤ Sign Up |
Japan | 3829118 | ➤ Sign Up |
South Africa | 200300406 | ➤ Sign Up |
Canada | 2416293 | ➤ Sign Up |
Taiwan | I361194 | ➤ Sign Up |
Portugal | 1648934 | ➤ Sign Up |
Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for SIGNIFOR
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
024 | Luxembourg | ➤ Sign Up | 92024, EXPIRES: 20260730 |
C0041 | France | ➤ Sign Up | PRODUCT NAME: CYCLO((4R)-4(2-AMINOETHYLCARBAMOYLOXY)-L-PROLYL-L-PHENYLGLYCYL-D-TRYPTOPHYL-L-LYSYL-4-O-BENZYL-L-TYROSYL-L-PHENYLALANYL-) : PASIREOTIDE, OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/12/753/001 20120424 |
00536 | Netherlands | ➤ Sign Up | PRODUCT NAME: PASIREOTIDE, DESGEWENST IN DE VORM VAN EEN ZOUT, IN HET BIJZONDER PASIREOTIDEDI-ASPARTAAT; REGISTRATION NO/DATE: EU/1/12/753/001-012 20120424 |
00716 | Netherlands | ➤ Sign Up | PRODUCT NAME: PASIREOTIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/12/753 20141119 |
701 | Luxembourg | ➤ Sign Up | PRODUCT NAME: PASIREOTIDE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE OU UN HYDRATE QUI EN DERIVE . FIRST REGISTRATION: 20141121 |
8 | Finland | ➤ Sign Up | |
1307486/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: PASIREOTID; REGISTRATION NO/DATE: SWISSMEDIC 61254 02.11.2012 |
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |